Stockreport

Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1

Athenex, Inc.  (ATNX) 
Last athenex, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.athenex.com
PDF BUFFALO, N.Y., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercial [Read more]